Bo Angelin

Bo Angelin is a Professor of Clinical Metabolic Research at Karolinska Institutet, Sweden. He serves as Director of the Karolinska Institutet/AstraZeneca Integrated Cardio Metabolic Centre (ICMC) and Team Leader at the Cardio Metabolic Unit (CMU). His primary affiliation is with the Department of Medicine, Huddinge, within Karolinska Institutet, a leading medical university.

• Research Focus: Cardiology and Cardiovascular Disease, Endocrinology and Diabetes, Gastroenterology and Hepatology
• Key Contributions: Investigates lipid metabolism, bile acid regulation, and metabolic diseases. Leads studies on dyslipidemias, such as familial hypercholesterolemia, and explores translational therapies targeting bile acid transport and cardiovascular dysfunction.

His work bridges clinical and basic research, with a focus on metabolic pathways, drug development (e.g., FXR agonists, ASBT inhibitors), and the molecular mechanisms underlying cardiovascular and liver diseases. Recent studies emphasize sex-specific metabolic adaptations, intergenerational effects of maternal obesity, and the role of circadian rhythms in bile acid physiology.

Labs/Teams: Directs the ICMC, a collaborative center with AstraZeneca, and leads the CMU, focusing on translational cardio-metabolic research.